Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

U.S. stocks closed another record-setting week with a muted performance Friday, as hope built on Wall Street that the U.S. economy can manage the rare feat of suppressing high inflation without ...

The Dow Jones Industrial Average reached a record high following a modest inflation report, spurring hopes for additional ...

The blue-chip Dow Jones Industrial Average closed at a record high today as investors welcomed a subdued inflation report ...

The Dow Jones Industrial Average edged up to another record high while declines in tech stocks pulled other indexes lower.

In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...

The Dow Jones Industrial Average closed at a record high, driven by investor optimism following a subdued inflation report.

Bristol Myers Squibb (BMY) is up more than +1% after gaining FDA approval for its Cobenfy drug to treat patients with schizophrenia. Amgen (AMGN) is up more than +1% after Cantor Fitzgerald initiated ...